IMMUNOLOGY AND CANCER IMMUNOTHERAPY RESEARCH PROGRAM

免疫学和癌症免疫治疗计划（ICIP）的目标是通过学术研究， 参与和合作的基础和临床免疫学家的努力，以发展被动和主动 免疫策略来治疗癌症。ICIP通过将已建立的和 经验丰富的NCI资助的临床试验专家与NCI资助的癌症免疫学家和免疫学家， 开发、设计、执行、有效监测并实现达特茅斯学院发起的免疫治疗试验， 肾细胞癌、黑素瘤、结肠癌、乳腺癌、胶质母细胞瘤和骨髓瘤。ICIP有18个 来自5个部门的成员和超过830万美元的资金总额，其中超过250万美元 来自NCI（31%）。自2003年以来，ICIP已经发表了190多篇论文，其中8%涉及项目内 13%的项目涉及跨项目合作。自2003年以来， ICIP内的免疫学专业知识的深度和深度得到了极大的加强和集中。ICIP 一直致力于发展癌症疫苗接种策略，目的是将这些 在达特茅斯进行临床试验。被动（T细胞过继治疗）和主动（树突状细胞 (DC)和基于分子的）疫苗，其中一些已经进入临床试验。的 这些试验的开发和执行大大受益于CCSG支持的共享 资源，尤其是免疫监测。加强了国际土著人民理事会的重点和发展， 由NCCC战略招聘关键的初级教师。反过来，他们的工作也得到了 NCCC试验项目支助，其中一些是CCSG支助的。ICIP的专业知识现在包括 科学领域对癌症疫苗的成功开发至关重要。建立一个关键的 大量的专家在明确界定的领域，使互动的“工作组”？ 在肿瘤免疫治疗领域具有特定目标的专家。ICIP成员研究自然免疫 对癌症的反应，即，肿瘤生长所引起的免疫和抑制区议会的角色 在介导肿瘤抑制以及肿瘤免疫中的作用， ICIP。基于分子的疫苗，以触发强大的细胞介导的免疫反应，以癌症正在 是为了转化成人类而开发的。ICIP已经为现在和未来的翻译制定了一个愿景， 癌症疫苗注射到人体内。

The goal of the Immunology and Cancer Immunotherapy Program (ICIP) is to unite through scholarly engagement and collaboration the efforts of basic and clinical immunologists to develop passive and active immunization strategies to treat cancer. ICIP adds value to NCCC by bringing together established and experienced NCI-funded, clinical trialists with NCI-funded cancer immunologists and immunologists to develop, design, execute, effectively monitor, and bring to fruition Dartmouth-initiated immunotherapy trials in renal cell carcinoma, melanoma, colon cancer, breast cancer, glioblastoma, and myeloma. ICIP has 18 members from 5 departments and more than $8.3 million in total funding, of which greater than $2.5 million derives from the NCI (31%). Since 2003, ICIP has published over 190 papers of which 8% involve intraprogrammatic collaborations and 13% involve inter-programmatic collaborations. Since 2003, the breadth and depth of the immunological expertise within the ICIP has been greatly strengthened and focused. ICIP has focused on the development of strategies to vaccinate against cancer, with the intent to move these strategies into clinical trials at Dartmouth. Both passive (T cell adoptive therapy) and active (dendritic cell (DC) and molecularly based) vaccines have been developed, some of which have entered clinical trials. The development and execution of these trials have greatly benefited from the CCSG-supported shared resources, especially Immune Monitoring. Enhanced ICIP focus and development has been facilitated by the strategic recruitment of key junior faculty by the NCCC. Their work, in turn, has been greatly facilitated by NCCC pilot project support, some of which was CCSG-supported. ICIP expertise now encompasses the scientific areas most important for the successful development of cancer vaccines. Establishment of a critical mass of experts in well-defined areas has enabled interactive "Working Groups"¿confederations of ICIP experts with specific goals in the area of tumor immunotherapy. ICIP members study the natural immune responses to cancer¿i.e., both the immunity and suppression elicited by a growing tumor. The role of DCs in mediating tumor suppression as well as tumor immunity is studied by a number of laboratories within the ICIP. Molecularly based vaccines to trigger robust cell-mediated immune responses to cancer are being developed for translation into humans. ICIP has formulated a vision for the present and future translation of cancer vaccines into humans.